Cirrhosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Rapidly progressive
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Morning myoclonic jerks
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Bone Pain, CTCAE 3.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Idiopathic pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Intellectual Disability
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Avascular necrosis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
EEG with polyspike wave complexes
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal myocardium morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Glomerulopathy Assessment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Avascular Necrosis, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Bone Pain, CTCAE 5.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Osteolysis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
4 genes, LAMP3, PIP5K1B, SCARB2 and TXNIP were identified in both groups; each displays significant biologic plausibility for a role in asthma.
|
24188128 |
2013 |
Peripheral demyelinating neuropathy
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Demyelinating neuropathy is a clinical clue to the presence of SCARB2 mutations in PME.
|
21670406 |
2011 |
Myoclonic Epilepsies, Progressive
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Progressive myoclonus epilepsy: extraneuronal brown pigment deposition and system neurodegeneration in the brains of Japanese patients with novel SCARB2 mutations.
|
23659519 |
2014 |
Myoclonus, Action
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
Action myoclonus renal failure (AMRF) syndrome is a rare form of progressive myoclonus epilepsy with renal dysfunction related to mutations in the SCARB2 gene.
|
24485911 |
2014 |
Myoclonic Epilepsies, Progressive
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Progressive myoclonus epilepsy without renal failure in a Chinese family with a novel mutation in SCARB2 gene and literature review.
|
29605618 |
2018 |
Gaucher Disease
|
0.070 |
Biomarker
|
disease |
BEFREE |
LIMP-2 was identified as a sorting receptor for beta-glucocerebrosidase (beta-GC), which is defective in Gaucher disease.
|
19933215 |
2010 |
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
LIMP-2 gene and protein expression was significantly increased in prostate cancer compared to nonmalignant cell lines (P ≤ 0.05).
|
24435746 |
2014 |
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
LIMP-2 gene and protein expression was significantly increased in prostate cancer compared to nonmalignant cell lines (P ≤ 0.05).
|
24435746 |
2014 |
Virus Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
SCARB2 or PSGL-1 receptor binding is the first step in the development of viral infections, and viral factors (e.g., 5' UTR, VP1, 3C, 3D, 3' UTR), host factors and environments (e.g., ITAFs, type I IFN) are also involved in viral infections.
|
24602216 |
2014 |
Action Myoclonus-Renal Failure Syndrome
|
0.800 |
Biomarker
|
disease |
BEFREE |
SCARB2/LIMP2 deficiency in action myoclonus-renal failure syndrome.
|
27582254 |
2016 |
Kidney Failure
|
0.050 |
Biomarker
|
disease |
BEFREE |
LIMP-2 deficiency is associated with neurological abnormalities and kidney failure and, as an acid glucocerebrosidase receptor, impacts Gaucher and Parkinson's diseases.
|
29199275 |
2017 |